

Press Release



Notice regarding Commencement of Insurance Coverage of ASKA Pharmaceutical drugs for the Indication of Infertility Treatment

TOKYO, April 1st, 2022 – ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi), announced today that it has insurance cover for the indications and benefits related to infertility treatment for the pharmaceutical drugs shown below.

Effectiveness and safety related to newly insured indications were evaluated based on the results of surveys of domestic use, and domestic and overseas medical practice guidelines, etc. as published and referenced in medical pharmacology.

[List of drugs for which indications related to infertility treatment have been insured]

Product Name	Generic name	*1 Insured indications
PLANOVAR TABLETS	Norgestrel Ethinylestradiol	Coordinating the timing of initiation of controlled ovarian hyperstimulation to induce the development of multiple follicles in Assisted Reproductive Technologies (hereafter “ART”)
GONATROPIN FOR INTRAMUSCULAR INJECTION 1000 units, 3000 units	Human Chorionic Gonadotrophin	Luteal phase support as part of an ART treatment
GONATROPIN FOR INJECTION 5000 units	Human Chorionic Gonadotrophin	<ul style="list-style-type: none">- Luteal phase support as part of an ART treatment- For ART program: triggering of final follicular maturation and luteinisation after stimulation of follicles.- Ovulation induction and luteinization in general infertility treatment (infertility treatment aimed at fertilization in the body)
HMG INTRAMUSCULAR INJECTION 75 units, 150 units “ASKA”	Human Menopausal Gonadotrophin	Controlled ovarian hyperstimulation to induce the development of multiple follicles in ART
uFSH INJECTION 75 units, 150 units “ASKA”	Purified Human Menopausal Gonadotrophin	Controlled ovarian hyperstimulation to induce the development of multiple follicles in ART

In addition, the following products have been listed in the NHI drug price list as of today.

Product Name	General name	*1 Indications
LUTEUM VAGINAL SUPPOSITORIES 400mg	Progesterone	*2 Luteal phase support as part of an ART treatment.

*1 This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.

*2 No change to Indications

Since its foundation in 1920, ASKA has been a pioneer in the field of hormone formulation, continuing to discover and provide pharmaceutical drugs. In particular, we have focused on the field of obstetrics and gynecology as a company that supports women's health. As a specialty pharma company in the field, we will continue to make further contributions to a healthy future for women.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp